Mesoblast Chief Executive Dr Silviu Itescu stated: "Our goal is for remestemcel-L to be the first commercially manufactured allogeneic cellular medicine available in the United States. The commercial success of TEMCELL HS Inj. ®7 in Japan by Mesoblast's licensee, JCR Pharmaceuticals Co. Ltd, in the treatment of steroid-refractory acute GVHD is very encouraging in light of our launch plans in the United States, where there is a substantially larger unmet need."